The partnership controlled by Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) plans to subscribe to 30 million yuan worth of shares of Zhongjun Jucheng.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that, in order to improve the utilization of funds and achieve the goal of high-quality asset allocation, the company will utilize the professional expertise of a professional organization. The company-controlled Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) (referred to as "Hangzhou Mipeng") intends to participate in the subscription of shares of Hangzhou Zhongjun Jucheng Equity Investment Partnership Enterprise (Limited Partnership) (referred to as "Zhongjun Jucheng") with the signing of a "Partnership Agreement" and related documents on November 20, 2024. Hangzhou Mipeng, as a limited partner, plans to subscribe to the corresponding capital contribution with its own funds of 30 million yuan. It is reported that the main investment projects of the partnership enterprise are high-quality enterprises in the unlisted medical health sector, including pharmaceuticals, devices, medical services, digital therapy, etc. This investment is beneficial for Hangzhou Mipeng, controlled by the company, to obtain a reasonable investment return. At the same time, the company can not only utilize the professional expertise of professional organizations to achieve high-quality asset allocation goals, improve the efficiency and return on capital operations of the company, but also the investment area and direction of the partnership enterprise have certain compatibility with the company's existing business and future development, which is conducive to the company seizing industry development opportunities and having a certain synergy with the company. The investment field of the partnership enterprise has a certain degree of synergy with the company, and there is potential for business cooperation between the invested projects and the company.